.

Deeper Knowledge, Faster

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Cerilliant
US Army
Julphar
Healthtrust
Medtronic
Cipla
Boehringer Ingelheim
Daiichi Sankyo
Merck
McKinsey

Generated: September 25, 2017

DrugPatentWatch Database Preview

Supernus Pharms Company Profile

« Back to Dashboard

What is the competitive landscape for SUPERNUS PHARMS, and when can generic versions of SUPERNUS PHARMS drugs launch?

SUPERNUS PHARMS has two approved drugs.

There are sixteen US patents protecting SUPERNUS PHARMS drugs. There is one tentative approval on SUPERNUS PHARMS drugs.

There are twenty-five patent family members on SUPERNUS PHARMS drugs in ten countries.

Summary for Applicant: Supernus Pharms

Patents:16
Tradenames:2
Ingredients:2
NDAs:2
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Supernus Pharms
TROKENDI XR
topiramate
CAPSULE, EXTENDED RELEASE;ORAL201635-003Aug 16, 2013RXYesNo► Subscribe► SubscribeY ► Subscribe
Supernus Pharms
TROKENDI XR
topiramate
CAPSULE, EXTENDED RELEASE;ORAL201635-004Aug 16, 2013RXYesYes► Subscribe► SubscribeY ► Subscribe
Supernus Pharms
TROKENDI XR
topiramate
CAPSULE, EXTENDED RELEASE;ORAL201635-003Aug 16, 2013RXYesNo► Subscribe► SubscribeY ► Subscribe
Supernus Pharms
TROKENDI XR
topiramate
CAPSULE, EXTENDED RELEASE;ORAL201635-001Aug 16, 2013RXYesNo► Subscribe► SubscribeY ► Subscribe
Supernus Pharms
OXTELLAR XR
oxcarbazepine
TABLET, EXTENDED RELEASE;ORAL202810-002Oct 19, 2012RXYesNo► Subscribe► SubscribeY ► Subscribe
Supernus Pharms
TROKENDI XR
topiramate
CAPSULE, EXTENDED RELEASE;ORAL201635-004Aug 16, 2013RXYesYes► Subscribe► SubscribeY ► Subscribe
Supernus Pharms
OXTELLAR XR
oxcarbazepine
TABLET, EXTENDED RELEASE;ORAL202810-001Oct 19, 2012RXYesNo► Subscribe► SubscribeY ► Subscribe
Supernus Pharms
TROKENDI XR
topiramate
CAPSULE, EXTENDED RELEASE;ORAL201635-004Aug 16, 2013RXYesYes► Subscribe► SubscribeY ► Subscribe
Supernus Pharms
TROKENDI XR
topiramate
CAPSULE, EXTENDED RELEASE;ORAL201635-001Aug 16, 2013RXYesNo► Subscribe► SubscribeY ► Subscribe
Supernus Pharms
TROKENDI XR
topiramate
CAPSULE, EXTENDED RELEASE;ORAL201635-001Aug 16, 2013RXYesNo► Subscribe► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for SUPERNUS PHARMS drugs

Drugname Dosage Strength Tradename Submissiondate
topiramate
Extended-release Capsules25 mg, 50 mg, and 100 mg
TROKENDI XR
5/12/2014
topiramate
Extended-release Capsules200 mg
TROKENDI XR
4/3/2014
oxcarbazepine
Extended-release Tablets150 mg and 300 mg
OXTELLAR XR
4/12/2013

Non-Orange Book Patents for Supernus Pharms

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,017,149Modified release preparations containing oxcarbazepine and derivatives thereof► Subscribe
9,119,792Modified release preparations containing oxcarbazepine and derivatives thereof► Subscribe
8,211,464Modified release preparations containing oxcarbazepine and derivatives thereof► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Supernus Pharms Drugs

Country Document Number Estimated Expiration
European Patent Office2026815► Subscribe
Australia2007319141► Subscribe
Canada2597740► Subscribe
European Patent Office1973528► Subscribe
Mexico2009001711► Subscribe
Spain2396051► Subscribe
Japan2010510241► Subscribe
Japan2009535351► Subscribe
Spain2360423► Subscribe
Spain2555066► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Supernus Pharms Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB95/028United Kingdom► SubscribePRODUCT NAME: TOPIRAMATE; REGISTERED: UK 0242/0301 19950718
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

US Army
Cerilliant
Express Scripts
Argus Health
Mallinckrodt
Accenture
Chinese Patent Office
Baxter
Merck
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot